top of page

Copper-67

Flat bottom of Erlenmeyer flask_edited.jpg
Image by Bosco Shots

Why Copper-67?

Copper-67 is often referred to as a "next-generation" radioisotope and is a highly valuable tool in precision medicine, particularly for treating Lymphoma, prostate cancer, and neuroendocrine tumours.

It is often positioned as a successor to Lutetium-177 (Lu-177) as it enables a true copper-based theranostic pair with superior imaging compatibility, flexible chemistry, and scalable accelerator production.

SCMR's view is that Cu-67 and Lu-177 will complement each other and sit side-by-side as a combined cancer-fighting tool.

While its clinical potential is immense, the global supply of Cu-67 is currently bottlenecked by a reliance on a small number of aging production facilities, a gap SCMR is designed to fill.

Technical Snapshot

Isotope: Copper-67 (Cu-67)

​

Half-life: ~61.8 hours
 

Decay Mode: Beta (Therapy) and Gamma (Imaging)
 

Key Reaction: Zn68(γ,p)Cu67
 

Primary Use: Targeted therapy for Lymphoma and neuroendocrine tumours; Theranostic imaging.

_edited.jpg

The Theranostic Advantage: "See and Treat"

What makes Cu-67 particularly attractive is its dual-emission profile, making it a true theranostic (Therapy + Diagnostic) agent:
 

  • Beta Particles for Treatment: It emits medium-energy beta particles that effectively destroy tumour cells.

     

  • Gamma Photons for Imaging: It simultaneously emits gamma photons that are perfectly suited for SPECT imaging, allowing physicians to visualise the isotope’s location within the body and monitor treatment progress in real-time.

     

  • Optimal Timing: With a half-life of approximately 62 hours, Cu-67 stays in the body long enough to deliver a therapeutic dose but clears quickly enough to minimise unnecessary radiation exposure.

The SCMR Production Pathway: Cleaner & Purer

While nuclear reactors can produce Copper-67, the process is often "messy," resulting in low specific activity and difficult-to-remove impurities. SCMR will utilise a high-energy electron accelerator and enriched zinc targets to create a superior product:
 

  • High Specific Activity: Our accelerator-based method ensures a higher concentration of the active isotope, which is crucial for effective radiopharmaceutical labeling.
     

  • Reduced Impurities: By using high-energy bremsstrahlung photons, we drive the Zn68(γ,p)Cu67 reaction, avoiding the competing reactions and "messy" radiochemistry common in reactor-based routes.
     

  • Reliable Regional Supply: By establishing this pathway in Australia, SCMR provides a secure, uranium-free alternative to the vulnerable global supply chain.

bottom of page